Although the role of MCT2 in cancer is not yet elucidated, a recent study showed that MCT2 knockdown suppressed KRAS mutant (the mutation in KRAS gene occurs in a big percentage of colorectal cancers and has been suggested to be associated with proliferation and decreased apoptosis in cancer cells) colorectal tumour growth in vivo, supporting the use of MCT2 as a promising target for inhibition of colorectal cancer 12. This evidence concerns the gene SLC16A7 and colorectal cancer.